Dr Maité FORMAGLIO & Dr Hélène MOLLION

Service de Neuropsychologie – Consultations Mémoire

The service is part of the memory resource research center (CMRR) of Lyon and in this context provides memory consultation dedicated to the diagnosis and treatment of patients with Alzheimer’s disease or related diseases, and more generally to cognitive disorders of neurobiological origin.

Memory consultations allow patients with memory disorders to benefit from a precise diagnosis and appropriate treatment for Alzheimer’s disease and other related diseases.

The service is especially involved in the care of young patients; he is correspondent for the National Reference Center for young patients with Alzheimer’s disease. Since 2015, a day hospital has received young patients with cognitive disorders as well as their caregivers, for multidisciplinary medical, psychological and social care.

Learn more

Bioran Team

Themes and axis research

The research activities of Dr Maité FORMAGLIO and Dr Hélène MOLLION are focused on Alzheimer’s disease and cognitively expressed pathologies.

The team is part of the French network of therapeutic trials in Alzheimer’s disease and participates in this framework in numerous research protocols, most of which are carried out thanks to local, national and even international collaborations. For example:

In brain imaging, in collaboration with CERMEP:

ROSBEF protocol: Evaluation of the role of serotonin in psycho-behavioral disorders of the behavioral variant of fronto-temporal lobar degeneration (cFTD).

This is a functional PET-MRI imaging study with [11C]DASB and [18F]altanserin. The main objective is to measure the differences in functioning of the brain serotonergic system between control subjects and cFTD patients. These parameters are evaluated for each subject, and compared between the two groups in order to highlight global and regional differences. Functional PET imaging data is complemented by anatomical and functional MRI imaging data, clinical and behavioral assessments, and biological and pharmacogenetic assessments. The aim is to highlight links between functional and anatomical PET and MRI imaging results, clinical scores and biological parameters. Funding from France Alzheimer.

On blood and CSF (Cerebrospinal Fluid) biomarkers for the diagnosis of neurodegenerative pathologies with cognitive expression, in collaboration with the neurochemistry sector of the CBPE of HCL (Laboratory of medical biology and pathological anatomy:

NfL – COG protocol: Study of the interest of plasma dosage of neurofilaments and a panel of biomarkers in the assessment of cognitive disorders of psychiatric and neurodegenerative origin. Multicenter study (CH le Vinatier, Dr Jean-Michel Dorey and Neurological Hospital, HCL) and prospective evaluation of the diagnostic performance of blood biomarkers in pathologies of neurodegenerative and psychiatric origin causing cognitive disorders (Alzheimer’s disease, lobar degeneration fronto-temporal, bipolar illness and psychotic disorders). Financing CSR le Vinatier.

QUIC-ASYN protocol: Transposition of the alphasynuclein detection protocol by RT-QuIC (Real Time-IQuaking Induced Conversion) method in brain tissue to the CSF of clinically well-characterized patients following MAGICC RCP (biologists/neurologists) and in collaboration with Neurobiotec (control population). The goal is to ultimately have an in vivo biomarker for the diagnosis of alphasynucleinopathies (Léwy body disease, Parkinson’s disease with or without cognitive disorders, multiple system atrophy). PAM-BAP call for projects.

In therapeutic trials, in connection with the CMRC of HCL (Mutualized Clinical Research Cell):

The team has actively participated for more than 15 years in clinical drug trials with industrial promotion of phases 1, 2 and 3 in Alzheimer’s disease at its different stages and in the evaluation of disease-modifying therapies and treatments. for symptomatic purposes. Recently, the CLARITY study from the EISAI laboratory evaluating in Phase 3 the tolerance and effectiveness of lecanemab (anti-amyloid antibody) in the early stages of Alzheimer’s disease and including national corodinatin was led by Dr Hélène MOLLION obtained a positive result. The treatment is currently being evaluated by the EMEA (positive phase III study, product currently being evaluated by the EMEA (European Medicines Evaluation Agency).

Collaborations

CRNL (Lyon Neuroscience Research Center) for the aforementioned protocols with:

-Drs Isabelle Quadrio, Anthony Fourier, Flora Kaczorowski, Mathieu Verdurand from the neurochemistry sector of the CBPE

-Dr Sophie Lancelot, radiopharmacist, CERMEP

-The CERMEP research team

-The BIORAN research team

Geriatric psychiatry team at CH Vinatier

Drs Jean-Michel Dorey and Herrmann as part of the NFL-COG protocol

Charpennes geriatrics team

Drs Antoine Garnier-Crussard and Sophie Dautricourt as part of the OFMEM national project, the ACTSOMA protocol (Joint analysis of spatial and ocular trajectories during aging and Alzheimer’s disease.), the LOCNES protocol (Locus Coeruleus and NEuropsychiatric Symptoms)

National collaborations:

-On the genetics of Alzheimer’s disease and amyloid angiopathy (Pr David Wallon, Pr Gaël Nicolas, Dr Lou Grangeon, neurology department and molecular genetics laboratory, Rouen University Hospital)

-On the genetics of fronto-temporal lobar degeneration, Competence Center for the Reference Center for Rare and Early Dementia (Pr. Marc Teichmann, ICM Pitié-Salpétrière)

-To the national Alzheimer research network (CHU Toulouse)

-At the Federation of Memory Centers, Memory Resources and Research Center, CHU Toulouse).

Publications

1. Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Laurencin C, Lancelot S, Brosse S, Mérida I, Redouté J, Greusard E, Lamberet L, Liotier V, Le Bars D, Costes N, Thobois S, Boulinguez P, Ballanger B.Brain. 2023 Oct 3.

2. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET.
Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, Ballanger B.Biomolecules. 2023 May 15;13(5):843.

3.Prospective 25-year surveillance of prion diseases in France, 1992 to 2016: a slow waning of epidemics and an increase in observed sporadic forms. Denouel A, Brandel JP, Peckeu-Abboud L, Seilhean D, Bouaziz-Amar E, Quadrio I, Oudart JB, Lehmann S, Bellecave P, Laplanche JL, Haik S.Euro Surveill. 2023 Dec;28(50).

4. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

5. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group.N Engl J Med. 2023 Nov 16;389(20):1862-1876.

6. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

7. Early-Onset Cerebral Amyloid Angiopathy and Alzheimer Disease Related to an APP Locus Triplication. Grangeon L, Cassinari K, Rousseau S, Croisile B, Formaglio M, Moreaud O, Boutonnat J, Le Meur N, Miné M, Coste T, Pipiras E, Tournier-Lasserve E, Rovelet-Lecrux A, Campion D, Wallon D, Nicolas G.Neurol Genet. 2021 Sep 8;7(5):e609.

8. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications.
Saracino D, Dorgham K, Camuzat A, Rinaldi D, Rametti-Lacroux A, Houot M, Clot F, Martin-Hardy P, Jornea L, Azuar C, Migliaccio R, Pasquier F, Couratier P, Auriacombe S, Sauvée M, Boutoleau-Bretonnière C, Pariente J, Didic M, Hannequin D, Wallon D; French Research Network on FTD/FTD-ALS; PREV-DEMALS and Predict-PGRN study groups; Colliot O, Dubois B, Brice A, Levy R, Forlani S, Le Ber I.J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1278-1288.

9. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease.
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit.Nat Med. 2021 Jul;27(7):1187-1196.

10. Improving the Diagnosis of the Frontal Variant of Alzheimer’s Disease with the DAPHNE Scale. Lehingue E, Gueniat J, Jourdaa S, Hardouin JB, Pallardy A, Courtemanche H, Rocher L, Etcharry-Bouyx F, Auriacombe S, Mollion H, Formaglio M, Rouaud O, Bretonnière C, Thomas-Antérion C, Boutoleau-Bretonnière C.J Alzheimers Dis. 2021;79(4):1735-1745.

11. Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer’s Disease Before 51 Years. Lacour M, Quenez O, Rovelet-Lecrux A, Salomon B, Rousseau S, Richard AC, Quillard-Muraine M, Pasquier F, Rollin-Sillaire A, Martinaud O, Zarea A, de la Sayette V, Boutoleau-Bretonniere C, Etcharry-Bouyx F, Chauviré V, Sarazin M, le Ber I, Epelbaum S, Jonveaux T, Rouaud O, Ceccaldi M, Godefroy O, Formaglio M, Croisile B, Auriacombe S, Magnin E, Sauvée M, Marelli C, Gabelle A, Pariente J, Paquet C, Boland A, Deleuze JF, Campion D, Hannequin D, Nicolas G, Wallon D; collaborators of the CNR-MAJ.J Alzheimers Dis. 2019;71(1):227-243.

Dr Maité FORMAGLIO & Dr Hélène MOLLION

Service de Neuropsychologie – Consultations Mémoire

Bioran Team

Themes and axis research

Collaborations

Publications

1. Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Laurencin C, Lancelot S, Brosse S, Mérida I, Redouté J, Greusard E, Lamberet L, Liotier V, Le Bars D, Costes N, Thobois S, Boulinguez P, Ballanger B.Brain. 2023 Oct 3.

2. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET.
Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, Ballanger B.Biomolecules. 2023 May 15;13(5):843.

4. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

6. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

mail

Adress

Navigation

Newsletter

Dr Maité FORMAGLIO & Dr Hélène MOLLION

Service de Neuropsychologie – Consultations Mémoire

Bioran Team

Themes and axis research

Collaborations

Publications

1. Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study. Laurencin C, Lancelot S, Brosse S, Mérida I, Redouté J, Greusard E, Lamberet L, Liotier V, Le Bars D, Costes N, Thobois S, Boulinguez P, Ballanger B.Brain. 2023 Oct 3.

2. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET.Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, Ballanger B.Biomolecules. 2023 May 15;13(5):843.

4. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

6. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

2. Distribution of α2-Adrenergic Receptors in the Living Human Brain Using [11C]yohimbine PET.
Laurencin C, Lancelot S, Merida I, Costes N, Redouté J, Le Bars D, Boulinguez P, Ballanger B.Biomolecules. 2023 May 15;13(5):843.

4. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.

6. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.
Escal J, Fourier A, Formaglio M, Zimmer L, Bernard E, Mollion H, Bost M, Herrmann M, Ollagnon-Roman E, Quadrio I, Dorey JM.J Neurol. 2022 Mar;269(3):1522-1529.